The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Convection-enhanced delivery for the treatment of brain tumors
Open accessAbstract
The brain is highly accessible for nutrients and oxygen, however delivery of drugs to malignant brain tumors is a very challenging task. Convection-enhanced delivery (CED) has been designed to overcome some of the difficulties so that pharmacological agents that would not normally cross the BBB can be used for treatment. Drugs are delivered through one to several catheters placed stereotactically directly within the tumor mass or around the tumor or the resection cavity. Several classes of drugs are amenable to this technology including standard chemotherapeutics or novel experimental targeted drugs. The first Phase III trial for CED-delivered, molecularly targeted cytotoxin in the treatment of recurrent glioblastoma multiforme has been accomplished and demonstrated objective clinical efficacy. The lessons learned from more than a decade of attempts at exploiting CED for brain cancer treatment weigh critically for its future clinical applications. The main issues center around the type of catheters used, number of catheters and their exact placement; pharmacological formulation of drugs, prescreening patients undergoing treatment and monitoring the distribution of drugs in tumors and the tumor-infiltrated brain. It is expected that optimizing CED will make this technology a permanent addition to clinical management of brain malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Jain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612
Cited by
Mahmoudi, K., Bouras, A., Bozec, D., Ivkov, R., & Hadjipanayis, C. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1430867 · Cited by 414
Dąbrowska, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21572 · Cited by 375
Mehta, A. M., Sonabend, A. M., & Bruce, J. N. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0520-4 · Cited by 331
Hennika, T., Hu, G., Olaciregui, N. G., Barton, K. L., Ehteda, A., Chitranjan, A., Chang, C., Gifford, A. J., Tsoli, M., Ziegler, D. S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169485 · Cited by 191
Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies
Wang, J., Garancher, A., Ramaswamy, V., & Wechsler-Reya, R. J. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-013838 · Cited by 113
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55
Metadata
- Authors
- Debinski, W., & Tatter, S. B.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2009-10
- Volume
- 9
- Issue
- 10
- Pages
- 1519-1527
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2005371778
- Cited by
- 168
- References
- 2
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.